

## Application of nuclear imaging using PET/SPECT techniques for assessment of CVD

Logo of the Center for Cardiovascular Physics Research & Center of Excellence in Nuclear Medicine, Gilan University of Medical Sciences.

**کاربرد تصویر برداری هسته ای به روش PET و SPECT در ارزیابی بیماری های قلبی و عروقی**

دبیر علمی کنفرانس: دکتر ارسلان سالاری

**سخنرانان:**

دکتر ارسلان سالاری: استاذ اقدامات مداخله ای قلب و عروق بزرگسال  
دکتر صغری فرضی پور: استادیار داروسازی هسته ای  
دکتر فاطمه جلالی: استادیار پزشکی هسته ای



دوره ۳ امتیاز باز آموزی

**۲۸ خرداد ۱۴۰۱**  
ساعت ۹ لغایت ۱۲

گروه های هدف: قلب و عروق، داخلی، داروسازی هسته ای، پزشکی هسته ای

ثبت نام از طریق سایت آموزش مداوم: <http://gilan.ircme.ir>  
لینک وبینار: <https://cmelearn.ir/course/181047>


Presented by: Dr. F. Jalali, MD, Assistant professor of Nuclear medicine



# Commonly used tracers


## $^{99m}\text{Tc}$ -Sestamibi

- Tc-99m is a radioactive compound
- Sestamibi is a lipophilic cation that has been labeled with TC-99m
- passively diffusion into the myocardial cell : because of its lipid solubility
- retain in myocardial cell and no redistribution.
- Half-life: 6hr
- Energy: 140kev
- Better image quality (intrinsically better & inject higher dose since  $\frac{1}{2}$  life is shorter



# $^{201}\text{Tl}$

- Energy: 69-83keV
- $\text{K}^+$  analogue : enter/ exit cell via  $\text{Na}^+/\text{K}^+$  ATPase pump.
- Half-life is 73hr (more radio active exposure to the patients)
- Unlike the Tc-99m perfusion agents, it then undergoes redistribution, a process of continual dynamic exchange between myocardial cells and the vascular blood pool.
- Worse imaging characteristics (intrinsically worse and also because need to limit dose to limit radioactive exposure)
- Assessment of viability



# Indication of MPI


- Detection of CAD
- Determination of significant of anatomic lesions detected by angiography
- Evaluating prognosis and risk stratification
- Assessing medical therapy of CAD
- Monitoring treatment effect after coronary revascularization
- Assessing cardiac viability
- Detect otherwise undetectable deficiencies (e.g. micro-circulatory)

# Risk stratification

## Risk of cardiac death or MI


- Low < 1% per year
  - Intermediate 1-3% per year
  - High > 3% per year
- 
- Normal or near normal exercise MPI even in presence of known angiographic CAD have a very low cardiac event rate (<1%)
- Subgroup where risk of a normal SPECT is >1%  warranty period of normal stress MPI was about 2 years
- Pharmacologic stress
  - Diabetics
  - Elderly patient
  - Patient with non-CAD

# Ischemic Cascade




# Basic principles of MPI

- Inject radioactive tracers whose distribution in the heart are proportional to the amount of blood flow to the area.
- Areas where tracers has been absorbed (normal blood flow) look different from areas that don't enough absorbed due to decreased blood flow.
- Gamma camera detects the photons given off by the radioactive tracers and thus the relative blood flow to the different areas d
- MPI detects “Relative, not absolute blood flow.





# Determinants of ischemia




**Relationship between blood flow and severity of coronary stenosis. At rest, myocardial blood flow is not reduced until a coronary stenosis approaches 90%. It then begins to drop off. However, with increased coronary blood flow produced by exercise or pharmacological stress, less severe stenoses (50–75%) result in reduced coronary flow.**

# Coronary Blood flow rates






**Rest MBF:**  
LAD normal  
RCA normal



**Stress MBF**  
LAD normal  
RCA attenuated relative to LAD




# MPI procedure

- MPI is comprised of two parts

**Stress phase:** Exercise or pharmacologic stress (dipyridamole, adenosine, dobutamine), with ECG monitoring.

**Rest phase:** When a myocardial perfusion imaging agent is injected at rest, myocardial uptake therefore will be homogenous



# Stress Testing

- Exercise stress test
- Pharmacologic Stress Testing
- Vasodilators:
  - Dipyridamole
  - Adenosine
  - Regadenoson
- dobutamine

# Preparation for exercise testing

- The patient must fast for 4 to 6 hours before the test to prevent gastric symptoms and minimize splanchnic blood distribution.
- Cardiac medications may be held depending on the indication for the stress test :diagnosis or to determine the effectiveness of therapy.
- Beta-blockers may prevent achievement of maximum heart rate. nitrate ,calcium channel blockers may block or prevent cardiac ischemia, limiting the test's diagnostic value.
- Hold caffeine, Methylxanthines, theophylline and Oral dipyridamole for at least 12-24 hours prior to testing
- Can give IV dipyridamole

In addition to a standard 12-lead electrocardiogram, an intravenous line is kept open.

# Stress Testing

- Exercise preferred mode of testing
- Can evaluate:
  - Exercise duration (functional capacity)
  - Symptoms
  - Heart-rate response/recovery
  - Blood-pressure response
  - EKG response
  - Arrhythmia
- treadmill exercise is usually performed according to the Bruce protocol
- degree of stress must be sufficient to unmask underlying ischemia. The adequacy of exercise is critical for interpretation.
- Degree of stress must be sufficient to unmask underlying ischemia.
- The adequacy of exercise is critical for interpretation.
- Patients achieving more than 85% of the age-predicted maximum heart rate ( $220 - \text{age}$ ) are considered to have achieved adequate exercise stress.
- Product of heart rate  $\times$  blood pressure & metabolic equivalents (METS) & exercise time (minutes) are also used to judge the adequacy of exercise.
- Tests should be symptom limited (not just 85% PMHR)

# Contraindications to Exercise testing

## **-Absolute**

- Contraindications Acute myocardial infarction, within 2 days
- High-risk unstable angina
- Uncontrolled cardiac arrhythmia with hemodynamic compromise
- Active endocarditis
- Symptomatic severe aortic stenosis
- Decompensated heart failure
- Acute pulmonary embolism or pulmonary infarction
- Acute myocarditis or pericarditis
- Physical disability that precludes safe and adequate testing

## **-Relative Contraindications**

- Known left main coronary artery stenosis
- Moderate aortic stenosis with uncertain relation to symptoms
- Tachyarrhythmias with uncontrolled ventricular rates
- Acquired complete heart block
- Hypertrophic cardiomyopathy with severe resting gradient
- Mental impairment with limited ability to cooperate

# Indication for terminating the exercise

- ST elevation ( $>1.0$  mm) in leads without Q waves due to prior MI (other than aVR, aVL, or V1) •
- Drop in systolic BP of  $>10$  mm Hg, despite an increase in workload, when accompanied by any other evidence of ischemia
- Moderate to severe angina
- Central nervous system symptoms (e.g., ataxia, dizziness, or near syncope)
- Signs of poor perfusion (cyanosis or pallor)
- Sustained ventricular tachycardia or other arrhythmia that interferes with normal maintenance of cardiac output during exercise
- Technical difficulties monitoring the ECG or systolic BP
- Patient's request to stop
- Relative Indications
- Marked ST displacement (horizontal or downsloping of  $>2$  mm) in a patient with suspected ischemia • Drop in systolic BP of  $>10$  mm Hg (persistently below baseline) despite an increase in workload, in the absence of other evidence of ischemia
- Increasing chest pain
- Fatigue, shortness of breath, wheezing, leg cramps, or claudication
- Arrhythmias other than sustained ventricular tachycardia, including multifocal ectopy, ventricular triplets, supraventricular tachycardia, atrioventricular heart block, or bradyarrhythmias
- Exaggerated hypertensive response (systolic blood pressure  $>250$  mm Hg and/or diastolic blood pressure  $>115$  mm Hg)
- Development of bundle branch block that cannot be distinguished from ventricular tachycardia

# Pharmacological stress testing

- Pharmacologic Stress Testing

- Vasodilators:

Dipyridamole

Adenosine

Regadenoson

- dobutamine


# Indication pharmacologic stress testing

- Patient unable/unwilling to exercise
- Contraindications for exercise-abdominal aortic aneurism, severe AS
- LBBB/Pacemaker
- Interfering medications
- Post MI( $\geq$ 1day) clinically stable patients

# Preparation for pharmacological stress


- Nothing to eat for at least 3 hours
- Hold caffeine, Methylxanthines, theophylline and Oral dipyridamole for at least 12-24 hours prior to testing
- Can give IV dipyridamole

# pharmacologic stress testing (vasodilator)



# Coronary flow in patient with CAD in


**Rest**



**Resultant Image Uniform**

**Flow maintained due to coronary autoregulation**

**Stress**



**Resultant Image Heterogeneous**

**Flow disparity due to augmented flow in normal bed and attenuated response in stenosed bed**


# Vasodilators

## Dipyridamole

- Indirect coronary artery vasodilator
- Prevents intracellular reuptake of adenosine
- Half-life 33–62 minutes
- Hyperemia >15 minutes

## Adenosine

- Coronary vasodilator-activation of cellular adenosine receptors
- A<sub>2</sub> receptor on smooth muscle
- vasodilation 3.5-5 x's blood flow
- Short half-life (2-10s vs.dipyridamole 33-62min)



# Regadenoson


- A2a receptor agonist
- Low affinity for A1 (AV block)
- Very weak A2a and A3(Bronchospasm)
- Dose (0.4mg)
- Rapid injections (10s) with immediate flush
- Radionuclide agent 10-20s after flush

# Contraindications to Dipyridamole/Adenosine

- Patient with bronchospastic lung disease
- Systolic BP less than 90mmHg
- Uncontrolled hypertension (systolic BP > 200mmHg or diastolic BP > 110mmHg)
- Ingestion of caffeinated foods or beverages
- Known hypersensitivity to dipyridamole
- Unstable angina, acute coronary syndrome or less than 2 to 4 days after an acute myocardial infarction

# Dobutamine

- Direct weak  $\beta_2$  and  $\alpha_1$  receptor agonist activity and a strong  $\beta_1$  agonist Dobutamine infusion results in direct related increase  $\beta_1$  and  $\beta_2$  stimulation with a dose in heart rate, BP, and myocardial contractility
- Onset of action is within 2 minutes of its infusion.
- Half-life 2-minute



# Contraindications for dobutamine

- Unstable angina, acute coronary syndrome, or less than 2 to 4 days after an acute myocardial infarction.
- Hemodynamically significant left ventricular outflow tract obstruction
- Atrial tachyarrhythmias with uncontrolled ventricular response
- Prior history of ventricular tachycardia.
- Uncontrolled hypertension (systolic BP >200 mmHg or diastolic BP >110 mmHg)
- Patients with aortic dissection
- Known hypersensitivity to dobutamine

# Image protocols

- 2-days  $^{99m}\text{Tc}$ -agent protocol
- **same-day**  $^{99m}\text{Tc}$ -agent protocol
- Dual isotope ( $^{201}\text{Tl}$ ,  $^{99m}\text{Tc}$ -sestamibi) same day protocol
- $^{201}\text{Tl}$  stress Reinjecion.
- $^{201}\text{Tl}$  redistribution protocol

# Imaging protocols

- **One-day protocol**
- Low dose, high dose  $^{99m}\text{Tc}$ -sestamibi same day protocol
  - Inject low dose of the tracer
  - Acquire image
  - Wait several hours for the tracers to decay
  - Inject a high dose of tracer for the patient
  - Acquire images again
  - Compare the pictures

- **2-days  $^{99m}\text{Tc}$ -agent protocol**
  - Inject high dose of tracer for rest and stress
  - Wait 1 day between the stress & rest images
  - Better for obese patient

# Different imaging protocols

- Dual isotope ( $^{201}\text{Tl}$ ,  $^{99\text{m}}\text{Tc}$ -sestamibi) same day protocol:
  - Inject  $^{201}\text{Tl}$  at rest
  - Acquire images
  - Advantage is that  $^{201}\text{Tl}$  &  $^{99\text{m}}\text{Tc}$ -sestamibi gives up slightly different energy of photons so pictures from the rest wouldn't contaminate the picture at stress.
  - Problems includes more radioactive exposure and difficulty in comparing  $^{201}\text{Tl}$  with  $^{99\text{m}}\text{Tc}$  images.



- $^{201}\text{Tl}$  redistribution protocol
  - Stress the patient and inject the tracer at peak stress
  - Image the patient immediately
  - Wait 3-4 hours and image the patient again
  - Can wait 24hours to assess viability

# Interpretation Sequence

- Review unprocessed data first
- Review myocardial slices: supine and prone breast up and breast down, AC & non-AC
- Quantitation
- ECG gated SPECT data

# Raw Data

- Patient motion (vertical and horizontal)
- Lung uptake
- Count density
- Attenuation
- Extracardiac activity



Ready

Quality Control Tests

S. Ready Column 30m

Match Control Series


Include:

Reset All Defaults


# SPECT Images

- Confirm orientation
- Align slices
- Normalize intensity
- Cavity size: Assess dilatation, TID
- Evaluate relative perfusion (including RV)
- Confirm defect in multiple projections
- Determine severity and extent
- High-risk or multi-vessel distribution








# Standard SPECT imaging display



# Standard SPECT imaging display



# General Principles of interpretation


| Interpretation | Normal   | Attenuation artifact  | Scar  | Ischemia  |
|----------------|--|---|---|---|
| Stress         |  |  |  |  |
| Rest           |  |  |  |  |
| Perfusion      | No defects   | Fixed defects   | Fixed defects   | Reversible defect   |
| Wall motion    | Normal   | Normal  | Abnormal  | Normal or abnormal  |

# Interpretation of MPI Images

➤ Interpretation should include:

- Location
- Size
- Severity
- Degree of reversibility
- Number of defects that represent different vascular territories

# Reversible Ischemia in anterior lateral and apical myocardium




# Extent and Severity

- **Severity qualitative**

- Mild decrease in counts compared to adjacent activity without the appearance of wall thinning
- Moderate: wall thinning
- Severe: defects that approach background activity

- **Severity semiquantitative**

- Normal perfusion 0
- Mild reduction in counts 1
- Moderate reduction in counts 2
- Severe reduction in counts 3
- Absent uptake 4



# Semiquantitative Analysis

- Summed Stress Score (SSS)
  - – Extent and severity of CAD
  - –  $SSS = \sum S$  stress segmental scores
- Summed Rest Score (SRS)
  - – Extent and severity of infarction
  - –  $SRS = \sum S$  rest segmental scores
- Summed Difference Score (SDS)
  - – Extent and severity of ischemia/reversibility
  - –  $SDS = SSS - SRS$


# Dr.Heshmat Nuclear Medicine Center Myocardial Perfusion Gated SPECT

Stress [Isotope: (A) - Recon - NoAC], 11-Jun-2022


SA




Rest [Isotope: (A) - Recon - NoAC], 11-Jun-2022



VLA



HLA



Patient Name: Biaras Bahram  
Study Date: 12-Jan-2022

Patient ID: 5179059577  
Study Name: Myocardial Perfusion

Sex: M

Age: 045Y

Data Selector

Quality Control

AutoRecon

Flexible Display

Hard Copy

Complete

Suspend

Setup

Anterior

Inferior

Apex to Base

Anterior


Inferior

Septal to Lateral

Anterior

Base

Inferior to Anterior




Name: Biaras, Bahram  
 Pat ID: 5179059577  
 Sex: MALE  
 Limits: --  
 TID: 1.13  
 LHR: --  
 SSS: 19 SRS: 6 SDS: 13  
 SS%: 28 SR%: 9 SD%: 19

Study: Myocardial Perfusion  
 Dataset: Stress [Isotope (A) - Autocardiac - No  
 Date: 2022-01-22 18:07:43  
 Status: QC=1.79, IR=0.32  
 Database: MaleStressMB  
 Volume: 56ml  
 Wall: 137ml, 176k  
 Defect: 51ml  
 Extent: 37%  
 TPD: 28%  
 Shape: 0.54 [SI], 0.85 [Ecc]

Study: Myocardial Perfusion  
 Dataset: Rest [Isotope (A) - Autocardiac - NoA  
 Date: 2022-01-12 10:16:06  
 Status: QC=3.44, IR=0.29  
 Database: MaleRestMB  
 Volume: 49ml  
 Wall: 129ml, 156k  
 Defect: 8ml  
 Extent: 7%  
 TPD: 6%  
 Shape: 0.53 [SI], 0.84 [Ecc]


|     | Stress |      | Rest |     | Rev |
|-----|--------|------|------|-----|-----|
|     | Ext    | TPD  | Ext  | TPD |     |
| APX | 94     | 9.0  | 0    | 0.1 | 94  |
| LAT | 20     | 3.5  | 2    | 0.9 | 18  |
| INF | 1      | 0.2  | 0    | 0.0 | 1   |
| SEP | 54     | 7.1  | 36   | 4.4 | 19  |
| ANT | 51     | 8.1  | 1    | 0.3 | 46  |
| TOT | 37     | 28.0 | 7    | 5.6 | 30  |



# Summed Stress Score

| SSS                                | Event rate |
|------------------------------------|------------|
| <4 normal                          | 0.3%       |
| 4–8 (mildly abnormal)              | 4.7%       |
| 9-13 (moderate)<br>>=13 (severely) | 10%        |

# ECG gating




# Gating data

| parameter | Systolic   | Diastolic                    |
|-----------|--|------------------------------|
| Global    | LVEF: Post stress/optional rest<br>EDV<br>ESV<br>SWM<br>SWT<br>Phase | PFR, TPFR,PER,<br>TPER, TTPF |
| Regional  | WM<br>WT<br>Phase  | -                            |


Semiquantitative assessment of wall motion

- 0 = Normal motion
- 1 = Mild hypokinesis
- 2 = Moderate hypokinesis
- 3 = Severe hypokinesis
- 4 = Akinesis
- 5 = Dyskinesis



Semiquantitative assessment of wall thickening

- 0- normal
- 1= mild reduction
- 2=Moderate or severe reduction
- 3= Absence of noticeable thickness increase



**TABLE 18.4 High-Risk Features**

**Myocardial Perfusion Imaging**

Large single or multiterritorial fixed and/or reversible myocardial perfusion defects involving >15% of the LV mass

Transient ischemic dilation of the left ventricle

Stress-induced myocardial stunning with a drop in LVEF poststress

Transient RV tracer uptake

Increased pulmonary tracer uptake

**Stress Test**

Significant (>3 mm) ST-segment depression

Prolonged ST-segment depression

ST depression at low workload

Multilead ST depression

ST-segment elevation (>1 mm)

Hypotension (>10 mm Hg) with exercise

Sustained ventricular tachycardia


*LVEF*, Left ventricular ejection fraction; *RV*, right ventricular.

If ST dep <0.5 give 0


Score  $\leq -11$  = 5 year survival  
72%

Score  $\geq +5$  = 5 year survival  
97%

### Duke Treadmill Score




= Exercise Time (min) – 5 x Maximal ST depression (mm) – 4 x Angina Index  
 Angina Index (No angina = 0, Angina = 1, Limiting Angina = 2)



# Lung uptake

- increased lung uptake (lung -to heart- ratio)  $> 0.5$  for  $^{201}\text{Tl}$  and  $>0.4$  for  $^{99\text{m}}\text{Tc-MIBI}$
- It is associated with an elevated left ventricular end-diastolic pressure, and indicates exercise-induced ischemia left ventricular dysfunction and severe multi-vessel CAD.
- lung uptake is also observed after pharmacologic stress and has a similar unfavorable significance.
- Not surprisingly, increased lung uptake occurs also in patients with severely decreased resting LVEF, with or without demonstrable exercise-induced ischemia



# Transient Left Ventricular Dilation

This pattern is more likely caused by apparent thinning of the myocardium by circumferential endocardial ischemia rather than true and persistent dilation of the left ventricular cavity.

At times this image pattern may occur without apparent regional perfusion abnormalities.

# Transient Right Ventricular Visualization

- This pattern indicates ischemic left ventricular dysfunction during exercise.
- The mechanism responsible for this indicating remains unknown but may involve either increased right ventricular strain or a relative decrease in count intensity in the left ventricle due to diffuse hypoperfusion.

